Eric Topol
LightNews LightNews
banner
erictopol.bsky.social
Eric Topol
@erictopol.bsky.social
140K followers 310 following 2.8K posts

physician-scientist, author, editor

https://www.scripps.edu/faculty/topol/
Ground Truths https://erictopol.substack.com
SUPER AGERS https://www.simonandschuster.com/books/Super-Agers/Eric-Topol/9781668067666

Videos

Eric Jeffrey Topol is an American cardiologist, scientist, and author. He is the founder and director of the Scripps Research Translational Institute, a professor of Molecular Medicine and Executive Vice-President at Scripps Research Institute, and a senior consultant at the Division of Cardiovascular Diseases at Scripps Clinic in La Jolla, California. .. more

Medicine 88%
Public Health 4%
Posts Replies Media Videos
Pinned
erictopol.bsky.social
Eric Topol @erictopol.bsky.social · May 27
A new cover for SUPER AGERS after making the NYT bestseller list. Thanks to you for making it the #1 ranked new non-fiction book on Amazon.
amazon.com/gp/new-relea...

Reposted by Eric J. Topol

dshaywitz.bsky.social
David Shaywitz @dshaywitz.bsky.social · 9h
Now out in & just in time for your long Thanksgiving drive: my annual podcast recs, from Acquired & Ground Truths @erictopol.bsky.social to Not Otherwise Specified @lisarosenbaum.bsky.social & Grand Rounds @ai.nejm.org to The Rest is History & excellence actually timmermanreport.com/2025/11/reco...
Recommended Podcasts (and A Few Books), 2025 Year-End Edition - TimmermanReport.com
It’s time for my annual feature: recommended podcasts (and a few books) for TR readers to consider. As usual, these suggestions generally steer clear of politics; they also aren’t the only podcasts I ...
timmermanreport.com

erictopol.bsky.social
Eric Topol @erictopol.bsky.social · 13h
Making the diagnosis :-)

erictopol.bsky.social
Eric Topol @erictopol.bsky.social · 13h
Semaglutide (Ozempic) failed to have clinical impact for slowing progression in people with mild Alzheimer’s disease in 2 large, placebo-controlled trials
novonordisk.com/content/nnco...
News Details
novonordisk.com

Reposted by Robert C. Richards

erictopol.bsky.social
Eric Topol @erictopol.bsky.social · 1d
We've enrolled more than 700 participants (of 1,000 planned) in 3 weeks to a randomized trial for treatment of #LongCovid
scripps.edu Scripps Research @scripps.edu · 3d
Founder and director of the Scripps Research Translational Institute, @erictopol.bsky.social, and Julia Moore Vogel, co–principal investigator of the Long COVID Treatment Trial, were featured in @wired.com, sharing insights on a nationwide study testing GLP-1s for long COVID.
Weight-Loss Drug Zepbound Is Being Tested as a Treatment for Long Covid
GLP-1s are being studied for a wide range of conditions. Now, scientists will test whether their anti-inflammatory properties can help alleviate symptoms of long Covid.
ow.ly

erictopol.bsky.social
Eric Topol @erictopol.bsky.social · 2d
How can FDA allow TV ads for GLP-1 drug microdosing without any data?
Not aware of a single published study.
youtube.com/watch?v=zIbz...
Rebel Wilson goes Micro with Noom
YouTube video by Noom
youtube.com

Reposted by Eric J. Topol

Reposted by John De Vos

erictopol.bsky.social
Eric Topol @erictopol.bsky.social · 3d
“I had hemophilia for nearly five decades. I went to Philadelphia and had a 45-minute infusion, and my hemophilia was gone.”
Genes-> Medicine

nature.com/articles/s41...

Reposted by Eric J. Topol

scripps.edu
Scripps Research @scripps.edu · 3d
Founder and director of the Scripps Research Translational Institute, @erictopol.bsky.social, and Julia Moore Vogel, co–principal investigator of the Long COVID Treatment Trial, were featured in @wired.com, sharing insights on a nationwide study testing GLP-1s for long COVID.
Weight-Loss Drug Zepbound Is Being Tested as a Treatment for Long Covid
GLP-1s are being studied for a wide range of conditions. Now, scientists will test whether their anti-inflammatory properties can help alleviate symptoms of long Covid.
ow.ly

erictopol.bsky.social
Eric Topol @erictopol.bsky.social · 3d
I wonder who could be behind all of this......

erictopol.bsky.social
Eric Topol @erictopol.bsky.social · 3d
right! And this is how the @nytimes.com covered it today on page A16

erictopol.bsky.social
Eric Topol @erictopol.bsky.social · 3d
Look forward to our Ground Truths podcast next week on @matthewcobb.bsky.social 's phenomenal book!

erictopol.bsky.social
Eric Topol @erictopol.bsky.social · 3d
Why is immune escape such a problem with SARS-CoV-2?
Analysis of >1,000 antibodies to the spike protein to help design a workaround plan
www.cell.com/cell-systems...
One thousand SARS-CoV-2 antibody structures reveal convergent binding and near-universal immune escape
Feng et al. analyze over 1,100 SARS-CoV-2 antibody structures, including all 13 clinical monoclonals, mapping 99% of the receptor-binding domain surface. Their study reveals convergent paratope archit...
www.cell.com

Reposted by Paul Glasziou, Steve Peers

erictopol.bsky.social
Eric Topol @erictopol.bsky.social · 3d
In agreement with my friend @kkjetelina.bsky.social who writes today: "I suggest the general public avoid the CDC website."
yourlocalepidemiologist.substack.com/p/cdc-false-...

www.wsj.com/health/healt...

erictopol.bsky.social
Eric Topol @erictopol.bsky.social · 3d
Hey @nytimes.com, why is this on page A16?

Reposted by Eric J. Topol

scripps.edu
Scripps Research @scripps.edu · 4d
Congratulations to Eric Topol, MD (@erictopol.bsky.social), Scripps Research EVP and founder of SRTI, who was listed among @usnews.com’s 2025 “Best Leaders”, recognized for his significant impact in business, education, health care and public service. More: ow.ly/cOTk50XuUvX

erictopol.bsky.social
Eric Topol @erictopol.bsky.social · 4d
It was already in turmoil